The Bottom Line Although AOD-9604, MOTS-c, Tesamorelin, Semaglutide, and Tirzepatide are often discussed together, they serve very different purposes
Based on that study, the FDA and the European Medicines Agency approved the medication to prevent loss of kidney function, kidney failure, cardiovascular events, and death in patients with CKD, making semaglutide the first GLP-1 receptor agonist approved for this indication
Safety Advantage: Semaglutide The risk of serious side effects from GLP-1 receptor agonists is relatively low, but common side effects like nausea, indigestion, and other forms of GI upset can be expected by most users.6 These digestive issues tend to fade as your body adjusts to the medication and you make lifestyle adjustments based on how the medication affects your metabolism
Management: Monitor blood glucose and appetite changes
The presence of semaglutide in a medical profile should alert the ophthalmologist to a potential risk, said Dr